Oral JAK inhibitors unlikely to be totally shut out in eczema by black box warning
Dermatologists point to several uptake openings for JAK inhibitors in moderate-to-severe eczema despite highly publicized side effect concerns.
By
Brands
Latest in
Brands
Regulatory roundup: Novartis rare disease drug sees approval chances rise after trial completes
Theravance's ampreloxetine and Novartis in rare disease are among recent events reviewed by GlobalData’s Investigative News team.
By
Regulatory roundup: BMS’s T lymphocyte immunotherapy tripped by lung cancer trial termination
Sanofi’s pemphigus asset, Artios solid tumor trial among recent events reviewed by GlobalData’s Investigative News team.
By
Regulatory roundup: Ology, MaxCyte make moves in women’s cancer with divergent approval chances
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
By
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said.
By
Akebia and GSK will grapple with heightened scrutiny of HIF PHIs after roxadustat concerns
The firms may struggle to convince regulators that their HIF PHIs don't share roxadustat’s safety concerns in CKD.
By
Regulatory roundup: Sanofi/Regeneron, J&J and Eyenovia boost approval chances with Phase III updates
Trial updates and data releases across the pharma space moved the needle when it came to several drugs’ approval and…
By
Trial of AbbVie’s NASH drug against severe Covid-19 enrols 25% of patients after a year
The investigator-led trial has so far recruited 45 out of 183 patients despite enrolment opening in July last year.
By